Welcome to our dedicated page for Pds Biotechnology Corporation news (Ticker: PDSB), a resource for investors and traders seeking the latest updates and insights on Pds Biotechnology Corporation stock.
PDS Biotechnology Corporation (NASDAQ: PDSB) delivers innovative immunotherapies through its Versamune® platform, targeting cancers and infectious diseases. This news hub provides investors and researchers with timely updates on clinical advancements, regulatory milestones, and corporate developments.
Access primary-source press releases and curated analysis covering PDSB's clinical trials, partnership announcements, and financial disclosures. Track progress across key areas: Phase II/III oncology studies, FDA communications, and strategic collaborations enhancing their nanoparticle-based therapies.
Our repository ensures you stay informed about critical developments in HPV-associated cancer treatments, combination therapy research, and infectious disease vaccine progress. Bookmark this page for direct access to PDSB's verified updates, eliminating the need to scour multiple sources.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced that its abstract, featuring updated data from the VERSATILE-002 study, has been selected for presentation at the 2023 ASCO Annual Meeting on June 5, 2023. This Phase 2 study investigates the safety and efficacy of PDS0101 combined with KEYTRUDA® in treating patients with HPV16-positive head and neck cancer. The study focuses on two groups: ICI-naïve and ICI-refractory patients. Preliminary results show that 77% of patients had disease stabilization or tumor shrinkage, with an 87% overall survival rate at 9 months. The presentation will be part of the Head and Neck Cancer session, highlighting PDS0101's potential as a targeted therapy for this growing patient demographic.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced it received $1.4 million from the sale of tax benefits to a profitable New Jersey corporation under the New Jersey Technology Business Tax Certificate Transfer program for State Fiscal Year 2021. This funding is crucial as the company transitions its lead asset, PDS0101, into a registrational trial aimed at treating HPV16-positive metastatic or recurrent head and neck cancer. The New Jersey program allows unprofitable tech companies to sell a portion of their net operating losses and R&D tax credits to profitable entities, turning tax credits into cash to support growth, R&D, and operations. PDS Biotech focuses on developing targeted immunotherapies for cancer and infectious diseases utilizing proprietary platforms like Versamune®.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced a Key Opinion Leader (KOL) Roundtable focusing on Interleukin-12 (IL-12) on April 21, 2023, from 8:00 to 9:00 AM ET. This event will explore the potential of PDS0301, a novel IL-12 fusion protein, in oncology. The roundtable, moderated by Dr. Lauren Wood, will feature presentations from notable experts including Dr. James Gulley and Dr. Jeffrey Schlom. PDS0301 aims to enhance T cell activity in the tumor microenvironment while minimizing systemic exposure, thus promising improved safety and tolerability. Registration is open, and a live webcast will be available on the company’s investor relations website. PDS Biotechnology is committed to advancing targeted immunotherapies for cancer and infectious diseases, with PDS0101 entering Phase 3 trials in 2023.
FAQ
What is the current stock price of Pds Biotechnology Corporation (PDSB)?
What is the market cap of Pds Biotechnology Corporation (PDSB)?
